dichlorphenamide
Sign in to saveAlso known as Daranide®, dichlofenamide, glauconide, Keveyis®, DICLOFENAMIDE, Dichlorophenamide, 4,5-dichloro-benzene-1,3-disulfonic acid diamide, 4,5-dichloro-1,3-benzenedisulfonamide
Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-disulfamoylbenzene class. Dichlorphenamide as a carbonic anhydrase inhibitor is used for the treatment of acute angle closure glaucoma. While Dichlorphenamide does contain two sulfate groups within the structure, it falls under the class of a first generation carbonic anhydrase Inhibitor.
Research
196 papers- Dichlorphenamide: A Review in Primary Periodic Paralyses.Drugs · 2016
- Review of the Diagnosis and Treatment of Periodic Paralysis.Muscle & nerve · 2018
- Dichlorphenamide for Refractory Hyperkalemic Periodic Paralysis.Journal of clinical neuromuscular disease · 2021
- Structure and mechanism of carbonic anhydrase.Pharmacology & therapeutics · 1997
- Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults.Pediatric neurology · 2019
via PubMed
Wikidata facts
- Mass
- 303.915
Show 5 more facts
- chemical formula
- C₆H₆Cl₂N₂O₄S₂
- canonical SMILES
- C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
- World Health Organisation international non-proprietary name
- dichlofenamide
- defined daily dose
- 0.1
- Commons category
- Diclofenamide
via Wikidata · CC0
~2 min read
Article
3 sectionsContents
- Uses
- Cost
- References
Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-disulfamoylbenzene class. Dichlorphenamide as a carbonic anhydrase inhibitor is used for the treatment of acute angle closure glaucoma. While Dichlorphenamide does contain two sulfate groups within the structure, it falls under the class of a first generation carbonic anhydrase Inhibitor.
==Uses== Diclofenamide was approved in the United States in 1958 as Daranide to treat glaucoma, Subsequently, it was found effective in cases of therapy-resistant epilepsy. In 2015, the medication was approved in the US under the name Keveyis as an orphan drug for the treatment of primary hypokalemic and hyperkalemic periodic paralysis.